ELTX
Elicio Therapeutics, Inc.Company Information
- Company Name
- Elicio Therapeutics, Inc.
- CIK
- CIK0001601485
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- ELTX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- ELTX
SEC filing data through
Insider Sentiment
- Last purchase
- 2023-12-22
- Last sale
- 2021-12-20
- Shares purchased (TTM)
- 1,213,000
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 3,930,260
- Shares outstanding
- 19,244,679
- Ownership
- 20.42%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- -23.49%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Related Party | - | - | - | - | - | - | - | 20 | - | - | - | - | ||||||
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 23 | 15 | 19 | 21 | 22 | 18 | 18 | 26 | 3 | 12 | 13 | 15 | ||||||
| Restricted Cash Current | - | - | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 2 | ||||||
| Prepaid Expense And Other Assets Current | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 3 | 3 | 2 | 3 | 3 | ||||||
| Assets Current | 25 | 16 | 19 | 21 | 23 | 21 | 21 | 31 | 7 | 14 | 16 | 20 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Right Of Use Asset | 4 | 5 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 7 | 7 | ||||||
| Restricted Cash Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Prepaid Expense Other Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 3 | 3 | ||||||
| Assets | 31 | 23 | 26 | 28 | 30 | 28 | 28 | 38 | 16 | 24 | 27 | 31 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 1 | 0 | 1 | 0 | 4 | 4 | 1 | 2 | 1 | 1 | 4 | 4 | ||||||
| Accrued Liabilities Current | 7 | 6 | 6 | 5 | 5 | 6 | 8 | 5 | 5 | 3 | 4 | 4 | ||||||
| Contract With Customer Liability Current | - | - | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 2 | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Liabilities Current | 9 | 7 | 8 | 7 | 10 | 11 | 12 | 9 | 8 | 6 | 10 | 11 | ||||||
| Deferred Compensation Share Based Arrangements Liability Current | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Liability Noncurrent | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | ||||||
| Convertible Long Term Notes Payable | - | - | - | - | - | 0 | 20 | - | - | - | 0 | - | ||||||
| Long Term Debt Noncurrent | 10 | 9 | 9 | 10 | 9 | - | 20 | - | - | - | - | - | ||||||
| Liabilities | 23 | 24 | 24 | 24 | 28 | 19 | 39 | 57 | 17 | 20 | 16 | 18 | ||||||
| Deferred Compensation Sharebased Arrangements Liability Classified Noncurrent | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
Statement Of Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | - | - | 0 | - | - | - | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Temporary Equity | ||||||||||||||||||
| Treasury Stock Common Value | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | ||||||
| Additional Paid In Capital | 262 | 244 | 235 | 230 | 218 | 214 | 183 | 161 | 160 | 159 | 154 | 147 | ||||||
| Temporary Equity Carrying Amount Attributable To Parent | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -254 | -245 | -234 | -226 | -216 | -205 | -194 | -180 | -161 | -154 | -142 | -133 | ||||||
| Stockholders Equity | 8 | -1 | 2 | 4 | 2 | 9 | -11 | -19 | -2 | 5 | 11 | 13 | ||||||
| Liabilities And Stockholders Equity | 31 | 23 | 26 | 28 | 30 | 28 | 28 | 38 | 16 | 24 | 27 | 31 | ||||||
| Temporary Equity Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Preferred Stock Par Or Stated Value Per Share | - | - | 0.01 | - | - | - | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | - | ||||||
| Preferred Stock Shares Authorized | - | - | 10 | - | - | - | 10 | 10 | 10 | 10 | 10 | - | ||||||
| Preferred Stock Shares Issued | - | - | 0 | - | - | - | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Preferred Stock Shares Outstanding | - | - | 0 | - | - | - | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Common Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Common Stock Shares Authorized | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | ||||||
| Series A Preferred Stock | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Common Stock Shares Issued | 22 | 19 | 18 | 17 | 16 | 16 | 11 | 11 | 10 | 10 | 10 | 8 | ||||||
| Series B Preferred Stock | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Shares Outstanding | 22 | 19 | 18 | 17 | 16 | 16 | 11 | 11 | 10 | 10 | 10 | 8 | ||||||
| Series C Preferred Stock | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Treasury Stock Common Shares | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialElicio Therapeutics, Inc. (ELTX) — SEC Financial Statements & Analysis
Elicio Therapeutics, Inc. (ELTX) is a pharmaceutical preparations company, incorporated in DE. Elicio Therapeutics, Inc. trades on Nasdaq as: ELTX. Elicio Therapeutics, Inc. (ELTX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, Elicio Therapeutics, Inc. carries a market cap of $75.25M, a P/E ratio of -1.99x, a P/B ratio of 9.48x, an enterprise value of $60.79M, and an EV/EBITDA multiple of -1.61x. On profitability, it posts a Return on Equity (ROE) of -774.56% and a Return on Assets (ROA) of -124.36%. Per share, it reports EPS of $-1.97, diluted EPS of $-1.97, free cash flow per share of $-1.96, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of -30.71% year-over-year, and EPS growth of -42.18% year-over-year. On the balance sheet, it maintains a current ratio of 2.77x, a quick ratio of 2.55x, working capital of $16.28M, a debt-to-equity ratio of 2.95x, a debt ratio of 0.75, an interest coverage ratio of -24.00x, free cash flow of $-37.71M (TTM), and net debt of $-14.46M. Figures sourced from SEC EDGAR.
- Market Cap
- $75.25M
- P/E TTM
- -1.99x
- EPS TTM
- $-1.97
- P/B TTM
- 9.48x
- ROE TTM
- -774.56%
- ROA TTM
- -124.36%
- Debt To Equity
- 2.95x
- Free Cash Flow TTM
- $-37.71M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Elicio Therapeutics, Inc. in?
Elicio Therapeutics, Inc. (ELTX) operates in the Pharmaceutical Preparations industry.
What exchange does ELTX trade on?
Elicio Therapeutics, Inc. (ELTX) trades on the Nasdaq.
Where is Elicio Therapeutics, Inc. incorporated?
Elicio Therapeutics, Inc. is incorporated in DE.
When was Elicio Therapeutics, Inc. (ELTX)'s most recent SEC filing?
Elicio Therapeutics, Inc. (ELTX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is ELTX's market cap?
Elicio Therapeutics, Inc. (ELTX) has a market capitalization of $75.25M as of 2026-06-30.
What is ELTX's EPS (earnings per share)?
Elicio Therapeutics, Inc. (ELTX)'s trailing twelve month EPS is $-1.97 as of 2026-06-30.
What is ELTX's ROE (return on equity)?
Elicio Therapeutics, Inc. (ELTX)'s trailing twelve month Return on Equity (ROE) is -774.56% as of 2026-06-30.
What is ELTX's ROA (return on assets)?
Elicio Therapeutics, Inc. (ELTX)'s trailing twelve month Return on Assets (ROA) is -124.36% as of 2026-06-30.
What is ELTX's EV/EBITDA?
Elicio Therapeutics, Inc. (ELTX)'s trailing twelve month EV/EBITDA is -1.61x as of 2026-06-30.